Philips to Introduce Latest Advancements In Digital Pathology at the European Congress of Pathology 2020 Virtual Event

December 4, 2020

Philips will introduce their latest advancements in digital pathology at the European Congress of Pathology 2020 virtual event, Dec. 6-8. Building on its strong portfolio to support oncology clinical decision-making, the company brings together the power of imaging, pathology, genomics, and longitudinal data with insights from artificial intelligence, to empower clinicians to deliver clear care pathways with predictable outcomes for every patient.

Pathology is vital to healthcare delivery, with 70% of decisions affecting a person’s life involving a laboratory or pathology test [1]. However, with current resource shortages, the growing volume of complex requests, and workflow inefficiencies across systems and departments, pathology labs are facing major pressures on multiple fronts.

Rather than viewing oncology as many single moments of care, Philips envisions a continuous care pathway empowered by integrated solutions for oncology and pathology that help transform and enhance multi-disciplinary workflows, including the oncology tumor board process. Critical patient data is made visible for both oncologists and pathologists, which allows them to collaborate more efficiently, to drive the right care in the right sequence at the right time.

By taking a systems view across the imaging enterprise, Philips leverages the power of smart diagnostic technologies and advanced informatics to remove the obstacles standing in the way of optimized workflows. The newly released Philips IntelliSite Pathology Solution features a leading-edge user experience (UX), enhancing the ease of use while helping streamline the imaging workflow in an automated digital solution. With this latest iteration, the company connects healthcare systems to scale digital operations and improve efficiency in high volume scanning, stimulate collaboration, and enable precision diagnosis.

Philips IntelliSite Pathology Solution offers an open, scalable, and interoperable platform that supports flexibility in deployments of image analysis software tools, strengthening Philips’s commitment to the Open Pathology platform. Other software tools allow developers and researchers to work with data natively in the iSyntax format for core research and algorithm development, enabling collaboration for education and the creation of third-party applications.

“A precise diagnosis informs the patient’s care pathway progress, from screening and diagnosis to treatment, monitoring, assessment, and the transition toward home care,” said Kees Wesdorp, Chief Business Leader Precision Diagnosis at Philips. ”Philips integrated solutions for oncology, including this latest enhancement in digital pathology, help empower the cancer care team to reach clinical treatment decisions based on richer dashboards, clinical images, reports, and structured patient data. The seamless integration of information into the oncology workflow will help improve the clinician experience and ultimately, patient outcomes.”

[1] Report of the Second Phase of the Review of NHS Pathology Services in England, Lord Carter of Coles.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version